Literature DB >> 17354113

Treatment inferred disease severity in Crohn's disease: evidence for a European gradient of disease course.

Frank L Wolters1, Catelijne Joling, Maurice G Russel, Jildou Sijbrandij, Marion De Bruin, Selwyn Odes, Lene Riis, Pia Munkholm, Paolo Bodini, Barbara Ryan, Colm O'Morain, Ioannis A Mouzas, Epameinondas Tsianos, Severine Vermeire, Estela Monteiro, Charles Limonard, Morten Vatn, Giovanni Fornaciari, Dolores Rodriguez, Wim Groot, Bjørn Moum, Reinhold W Stockbrügger.   

Abstract

OBJECTIVE: Geographic differences in disease course of Crohn's disease (CD) might possibly be related to differences in genetic and environmental factors encountered in different parts of the world. The aim of this study was to assess differences in treatment regimens within a European cohort of CD patients as a reflection of disease course, and to identify associated phenotypic risk factors at diagnosis.
MATERIAL AND METHODS: A prospective European population-based inception cohort of 380 CD patients was studied. The patients were classified for phenotype according to the Vienna classification. Differences between Northern and Southern European centres in treatment over the first 10 years of disease were analysed using a competing risks survival analysis method.
RESULTS: Patients in the North were more likely to have had surgery (p<0.01), whereas patients in the South were more likely to have been treated medically (p<0.01). Phenotype at diagnosis was not predictive of differences in treatment regimens between North and South.
CONCLUSIONS: In this study, a difference in management of CD was observed between Northern and Southern European centres. This suggests that there may be a North-South disease severity gradient across Europe. Phenotypic differences between patients in the North and South did not explain this observed difference.

Entities:  

Mesh:

Year:  2007        PMID: 17354113     DOI: 10.1080/00365520600930750

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  9 in total

1.  Findings from the European collaborative inflammatory bowel disease database.

Authors:  Pia Munkholm
Journal:  Gastroenterol Hepatol (N Y)       Date:  2007-10

2.  Recent Research in IBD Epidemiology.

Authors:  Morten H Vatn
Journal:  Gastroenterol Hepatol (N Y)       Date:  2008-06

3.  Impact of pain on health-related quality of life in patients with inflammatory bowel disease.

Authors:  Anja Schirbel; Anne Reichert; Stephanie Roll; Daniel C Baumgart; Carsten Büning; Bianca Wittig; Bertram Wiedenmann; Axel Dignass; Andreas Sturm
Journal:  World J Gastroenterol       Date:  2010-07-07       Impact factor: 5.742

Review 4.  Vitamin D and the Pathogenesis of Inflammatory Bowel Disease.

Authors:  Berkeley N Limketkai; Matthew L Bechtold; Douglas L Nguyen
Journal:  Curr Gastroenterol Rep       Date:  2016-10

Review 5.  Epidemiology and clinical course of Crohn's disease: results from observational studies.

Authors:  Øistein Hovde; Bjørn A Moum
Journal:  World J Gastroenterol       Date:  2012-04-21       Impact factor: 5.742

6.  A changing trend in the management of patients with newly diagnosed Crohn's disease.

Authors:  A Qasim; N Ullah; P Crotty; N Swan; N Breslin; B Ryan; W Torreggiani; E Eguare; P Neary; H O'Connor; C O'Morain
Journal:  Ir J Med Sci       Date:  2011-03-23       Impact factor: 1.568

Review 7.  How expensive is inflammatory bowel disease? A critical analysis.

Authors:  Selwyn Odes
Journal:  World J Gastroenterol       Date:  2008-11-21       Impact factor: 5.742

8.  Oral vitamin D3 supplementation reduces monocyte-derived dendritic cell maturation and cytokine production in Crohn's disease patients.

Authors:  Lars E Bartels; Mia Bendix; Christian L Hvas; Søren P Jørgensen; Jørgen Agnholt; Ralf Agger; Jens F Dahlerup
Journal:  Inflammopharmacology       Date:  2013-12-29       Impact factor: 4.473

9.  Treatment Pathways Leading to Biologic Therapies for Ulcerative Colitis and Crohn's Disease in the United States.

Authors:  Corey A Siegel; Fei Yang; Sergio Eslava; Zhaohui Cai
Journal:  Clin Transl Gastroenterol       Date:  2020-02       Impact factor: 4.396

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.